Cosmo Pharmaceuticals N.V. (SWX: COPN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
62.30
-0.20 (-0.32%)
Nov 20, 2024, 3:40 PM CET
61.82%
Market Cap 1.00B
Revenue (ttm) 178.46M
Net Income (ttm) 66.99M
Shares Out 16.05M
EPS (ttm) 4.16
PE Ratio 15.00
Forward PE 8.99
Dividend 1.87 (2.99%)
Ex-Dividend Date Jul 10, 2024
Volume 10,810
Open 62.90
Previous Close 62.50
Day's Range 62.30 - 63.40
52-Week Range 38.20 - 80.60
Beta 1.25
Analysts n/a
Price Target n/a
Earnings Date Oct 24, 2024

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive... [Read more]

Sector Healthcare
Founded 1997
Employees 325
Stock Exchange SIX Swiss Exchange
Ticker Symbol COPN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Cosmo Pharmaceuticals gets new finance chief

Cosmo Pharmaceuticals N.V. appoints Svetlana Sigalova as new CFO, succeeding Niall Donnelly effective November 11, 2024.

5 weeks ago - Seeking Alpha